Shopping Cart
- Remove All
- Your shopping cart is currently empty
MY05 selectively targets c-MYC within cells and disrupts the interaction between MYC and MAX. It binds to intracellular c-MYC, modulating its thermal stability, reducing the transcriptional targets of c-MYC, and exhibiting anticancer activity (TNBC, triple-negative breast cancer).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | MY05 selectively targets c-MYC within cells and disrupts the interaction between MYC and MAX. It binds to intracellular c-MYC, modulating its thermal stability, reducing the transcriptional targets of c-MYC, and exhibiting anticancer activity (TNBC, triple-negative breast cancer). |
In vitro | MY05 exhibits IC 50 values of 10.6 μM, 13.5 μM, and 39.4 μM against MDA-MB 231, MDA-MB 468, and MCF-7 cell lines, respectively. It induces apoptosis and inhibits the growth of MYC-driven breast tumor spheres. |
In vivo | In a mouse model of triple-negative breast cancer (TNBC), MY05 (10 mg/kg) effectively inhibits the growth of MYC-driven solid tumors. |
Molecular Weight | 346.77 |
Formula | C19H11ClN4O |
Cas No. | 667909-97-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.